Exocrine Pancreatic Insufficiency Epi Market
The Exocrine Pancreatic Insufficiency (EPI) market report provides current treatment practices, emerging drugs, Exocrine Pancreatic Insufficiency (EPI) market share of the individual therapies, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Exocrine Pancreatic Insufficiency (EPI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Exocrine Pancreatic Insufficiency (EPI) Market Outlook
The Exocrine Pancreatic Insufficiency (EPI) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Exocrine Pancreatic Insufficiency (EPI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Exocrine Pancreatic Insufficiency (EPI) market in 7MM is expected to change in the study period 2017-2030.
Key Findings
This section includes a glimpse of the Exocrine Pancreatic Insufficiency (EPI) 7MM market.
Scope of the Report
Table of contents
1 Key Insights
2 Executive Summary
3 SWOT Analysis
4 Exocrine Pancreatic Insufficiency (EPI) Market Overview at a Glance
4.1 Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2017
4.2 Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2030
5 Disease Background and Overview: Exocrine Pancreatic Insufficiency (EPI)
5.1 Introduction
5.2 Biology and pathology of Exocrine Pancreatic Insufficiency
5.3 Pathophysiology of EPI
5.4 Causes and Risk Factors of EPI
5.4.1 EPI caused by pancreatic disorders
5.4.2 EPI caused by extrapancreatic disorders
5.5 Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis
5.5.1 Disorders of Carbohydrate Metabolism
5.5.2 Disorders of Lipid Metabolism
5.6 Diagnosis
5.6.1 Fecal elastase-1 test (FE-1)
5.6.2 Serum trypsinogen
5.6.3 Fecal chymotrypsin
5.6.4 Breath tests
5.6.5 Coefficient of fat absorption (CFA)
5.6.6 Preoperative Evaluation
5.6.7 Direct pancreatic function test
5.6.8 Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP)
5.6.9 Differential Diagnosis of exocrine pancreatic insufficiency
6 Recognized Establishments
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 7 Major Markets
7.2.1 Prevalence of Causative Indications of EPI in the 7MM
7.2.2 Prevalence of Exocrine Pancreatic Insufficiency in the 7MM
8 Country-wise Epidemiology of Exocrine Pancreatic Insufficiency (EPI)
8.1 Assumption and Rationale
8.1 United States
8.1.1 Prevalence of Causative Indications of EPI in the United States
8.1.2 Prevalence of Exocrine Pancreatic Insufficiency in the United States
8.2 EU5 Countries
8.2.1 Assumption and Rationale
8.3 Germany
8.3.1 Prevalence of Causative Indications of EPI in Germany
8.3.2 Prevalence of Exocrine Pancreatic Insufficiency in Germany
8.4 France
8.4.1 Prevalence of Causative Indications of EPI in France
8.4.2 Prevalence of Exocrine Pancreatic Insufficiency in France
8.5 Italy
8.5.1 Prevalence of Causative Indications of EPI in Italy
8.5.2 Prevalence of Exocrine Pancreatic Insufficiency in Italy
8.6 Spain
8.6.1 Prevalence of Causative Indications of EPI in Spain
8.6.2 Prevalence of Exocrine Pancreatic Insufficiency in Spain
8.7 The United Kingdom
8.7.1 Prevalence of Causative Indications of EPI in the United Kingdom
8.7.2 Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom
8.8 Japan
8.8.1 Assumption and Rationale
8.8.2 Prevalence of Causative Indications of EPI in Japan
8.8.3 Prevalence of Exocrine Pancreatic Insufficiency in Japan
9 Treatment
9.1.1 Dietary management and lifestyle changes
9.1.2 Pancreatic enzyme replacement therapy (PERT)
9.1.3 Patient Journey of EPI with Gastrointestinal Disorders in Diabetes
10 Unmet Needs
11 Marketed Drugs
11.1 Key-cross Competition
11.2 Pertzye (pancrelipase): Digestive Care
11.2.1 Product Description
11.2.2 Regulatory Milestone
11.2.3 Other Developmental Activities
11.2.4 Safety and Efficacy
11.2.5 Product Profile
11.3 Creon (pancrelipase)/Lipacreon: AbbVie
11.3.1 Product Description
11.3.2 Regulatory Milestone
11.3.3 Other Developmental Activities
11.3.4 Safety and Efficacy
11.3.5 Pipeline Activity
11.3.6 Product Profile
11.4 Zenpep (pancrelipase): Nestle
11.4.1 Product Description
11.4.2 Regulatory Milestone
11.4.3 Other Developmental Activities
11.4.4 Safety and Efficacy
11.4.5 Product Profile
11.5 Pancreaze: Janssen Pharmaceuticals
11.5.1 Product Description
11.5.2 Regulatory Milestone
11.5.3 Other Developmental Activities
11.5.4 Safety and Efficacy
11.5.5 Product Profile
11.6 Viokace (pancrelipase): Aptalis Pharma/Forest Laboratories
11.6.1 Drug Description
11.6.2 Regulatory Milestones
11.6.3 Other Development Activities
11.6.4 Safety and Efficacy
11.6.5 Product Profile
11.7 RELiZORB: Alcresta Therapeutics
11.7.1 Product Description
11.7.2 Regulatory Milestone
11.7.3 Other Developmental Activities
11.7.4 Safety and efficacy
11.7.5 Product Profile
11.8 Ultresa (pancrelipase): Aptalis Pharma/Forest Laboratories
11.8.1 Drug Description
11.8.2 Regulatory Milestones
11.8.3 Other Development Activities
11.8.4 Safety and Efficacy
11.8.5 Product Profile
12 Emerging Drugs
12.1 Omeprazole: Chiesi Farmaceutici
12.1.1 Product Description
12.1.2 Clinical Development
12.1.3 Product Profile
12.2 MS1819-SD: AzurRx BioPharma
12.2.1 Product Description
12.2.2 Other Developmental Activities
12.2.3 Clinical Development
12.2.4 Product Profile
13 Exocrine Pancreatic Insufficiency (EPI): 7 Major Market Analysis
13.1 Key Findings
13.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI) in the 7MM Countries
13.1.1 Market Size by Therapies
14 Conjoint Analysis
15 7MM Market Outlook
16 United States Market Size
16.1.1 Total Market size of Exocrine Pancreatic Insufficiency (EPI)
16.1.2 Market Size by Therapies
17 EU-5 Market Size
17.1 Germany
17.1.1 Total Market size of Exocrine Pancreatic Insufficiency (EPI)
17.1.2 Market Size by Therapies
17.2 France
17.2.1 Total Market size of Exocrine Pancreatic Insufficiency (EPI)
17.2.2 Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies
17.3 Italy
17.3.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.3.2 Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies
17.4 Spain
17.4.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.4.2 Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies
17.5 United Kingdom
17.5.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.5.2 Market Size by Therapies
17.6 Japan Market Size
17.6.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.6.2 Market Size by Therapies
18 Access and Reimbursement Overview: Exocrine Pancreatic Insuffficiency (EPI)
19 Case Reports
19.1 A Case Report of exocrine pancreatic insufficiency in palliative care patient
19.2 Case Report of a Patient with Pancreatic Exocrine Insufficiency and Enteral Feeding
19.3 Case Report of a Pancreatic Exocrine Insufficiency Patient with Systemic Edema after Pancreaticoduodenectomy
20 Market Drivers
21 Market Barriers
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight
Request for sample pages @ Exocrine Pancreatic Insufficiency (EPI) Market
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/